Drug Interaction Between Wellbutrin (Bupropion) and Vraylar (Cariprazine)
There is a clinically significant pharmacokinetic interaction between bupropion and cariprazine that requires dose adjustment of cariprazine when used together. Bupropion is a CYP2D6 inhibitor, and while cariprazine metabolism is not primarily dependent on CYP2D6, the combination warrants careful monitoring due to bupropion's effects on other metabolic pathways and the potential for additive side effects 1, 2.
Pharmacokinetic Considerations
Bupropion acts as a CYP2D6 inhibitor, which can increase plasma concentrations of drugs metabolized by this pathway 1. However, cariprazine is primarily metabolized by CYP3A4, not CYP2D6, and CYP2D6 poor metabolizer status does not have clinically relevant effects on cariprazine pharmacokinetics 2. This means the direct metabolic interaction risk is lower than with drugs heavily dependent on CYP2D6.
The FDA label for Wellbutrin explicitly states that bupropion and its metabolites are CYP2D6 inhibitors and can increase exposures of CYP2D6 substrates, particularly antipsychotics like haloperidol, risperidone, and thioridazine 1. While cariprazine is not listed as a specific concern, the general caution about antipsychotic combinations applies.
Pharmacodynamic Interactions and Safety Profile
The primary concern is additive side effects rather than metabolic interaction. Both medications can affect the central nervous system through different mechanisms:
Seizure risk: Bupropion lowers the seizure threshold (0.1% risk in clinical trials) and is contraindicated in patients with seizure disorders 3, 4. When combined with antipsychotics, which also lower seizure threshold, extreme caution is warranted 1.
Neuropsychiatric effects: Both drugs carry warnings about neuropsychiatric symptoms. Bupropion has been associated with mood changes, agitation, and restlessness 3, 4. Cariprazine's most common side effects include akathisia/restlessness, which occurred in 22.3% of patients in clinical trials 5, 6.
Dopaminergic effects: Bupropion has dopamine agonist effects through norepinephrine/dopamine reuptake inhibition 1. Cariprazine is a dopamine D3/D2 receptor partial agonist 7, 6. The combination could theoretically produce cumulative dopaminergic effects, though this is less concerning than with full dopamine agonists like levodopa.
Clinical Recommendations
When combining these medications:
Start with standard cariprazine dosing (1.5 mg/day for depression, as this was the effective dose in trials) 5, 8, since CYP2D6 inhibition by bupropion does not significantly affect cariprazine levels 2.
Monitor closely for akathisia and restlessness, as both drugs can cause these symptoms. If akathisia develops, consider dose reduction of cariprazine before adding anticholinergic medications 5, 6.
Assess seizure risk factors before initiating the combination. Avoid this combination in patients with:
Monitor for neuropsychiatric symptoms including worsening depression, suicidal ideation, agitation, or mood changes, particularly in the first 4-8 weeks 3, 4.
Watch for metabolic effects from cariprazine, though it has a favorable metabolic profile compared to other antipsychotics 6, 9. Bupropion may actually help mitigate weight gain 1.
Special Populations
In patients with depression requiring augmentation, this combination is rational and supported by evidence. Cariprazine 1.5-3 mg/day as adjunctive therapy to antidepressants (including bupropion) showed efficacy in treating major depressive disorder with inadequate antidepressant response 5, 8. The 1.5 mg dose was more consistently effective than 3 mg for adjunctive treatment 10, 5.
Avoid high-fat meals with cariprazine when combined with bupropion, as this can significantly increase cariprazine exposure 4, 2.